Company profile / LAURUSLABS

Laurus Labs earnings calls.

Other · 12 quarters tracked · source-linked performance, management guidance and promise context.

Research layer active
PositiveCredibility 0/100Latest record q4-fy26

Latest revenue

₹1,812 Cr

verified financial record

Quarters tracked

12

source records in the directory

Delivery assessment

0

Across 23 tracked commitments: 0 delivered, 23 missed.

Call date

2026-05-13

latest available source date

Signal trajectory

10 actual quarters
EBITDA (₹ Cr)PositiveWatchNegative
10 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q1 FY24: 168 · Watch source sentimentQ1 FY24Q2 FY24: 188 · Watch source sentiment · 2023-10-27Q2 FY24Q3 FY24: 183 · Watch source sentiment · 2024-01-17Q3 FY24Q1 FY25: 171 · Watch source sentimentQ1 FY25Q2 FY25: 182 · Watch source sentiment · 2024-11-07Q2 FY25Q3 FY25: 285 · Positive source sentimentQ3 FY25Q1 FY26: 389 · Positive source sentimentQ1 FY26Q2 FY26: 429 · Positive source sentiment · 2025-11-14Q2 FY26Q3 FY26: 485 · Positive source sentimentQ3 FY26Q4 FY26: 1,826 · Positive source sentiment · 2026-05-13Q4 FY261,826168
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Current read

0/100

Across 23 tracked commitments: 0 delivered, 23 missed.

Latest source read

What changed this quarter?

Open quarter read

Laurus Labs delivered a strong FY26 with revenue of ₹6,813 crore (+23% YoY) and EBITDA margin expansion of 670 bps to 26.8%, driven by a 38% surge in small molecule CDMO (₹1,896 crore) and 18% growth in affordable medicines (₹4,733 crore). PAT jumped 148% to ₹889 crore as gross margins improved to 60.4% on better mix and raw material softening. Management guided for continued CDMO growth, with capex of ₹3,000 crore over two years for capacity expansion (Unit 7, peptide, fermentation). However, geopolitical disruptions could pressure raw material availability and logistics, posing near-term headwinds for the generics business.

Colored figures compare against the previous available record. Hover or focus one for the comparison.

Signal

Positive

Revenue

₹1,812 Cr

Source date

2026-05-13

Across the record

Quarter history.

12 source records

History modules

Follow the numbers and themes.

Revenue history PAT history Margin trend Guidance tracker Bear-case history Language trends FY26 summary